Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

Age Group
0-9 years 10-17 years 18-26 years 27 years and older

2 3

Genetic Double Helix Genetic
Gene-modified (GM) T cell therapy
Trial Summary & Details
Ages: Child, Adult, Older Adult
Condition: Neoplasms

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.

Subjects who received at least one GM T cell infusion, will be asked to roll-over to this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

City of Hope National Medical Center, Duarte, CA
Emory University, Atlanta, GA
Massachusetts General Hospital, Boston, MA
Mayo Clinic, Rochester, MN
University of Nebraska Medical Center, Omaha, NE
Hackensack University Medical Center, Hackensack, NJ
Icahn School of Medicine at Mount Sinai Medical Center, New York, NY
Sarah Cannon Research Institute Center for Blood Cancers, Nashville, TN
University of Texas Southwestern Medical Center, Dallas, TX
The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Director Clinical Trial Disclosure